Investigational drug · Phase 2
SPL84
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cystic Fibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SPL84"
First trial start
2024
Jun 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPL84", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cystic Fibrosis
Approved drugs for the same conditions: Cystic fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "SPL84" as an intervention, largest first.
SpliSense Ltd.Industry
NCT06429176 · 64 participants (planned) · Start Jun 24, 2024 · Primary completion Oct 1, 2027
Drug: SPL84 · For: Cystic Fibrosis
Sites: Long Beach, California; Los Angeles, California; San Francisco, California · 27 sites in all
SpliSense Ltd.Industry
NCT06217952 · 32 participants · Start Feb 5, 2023 · Primary completion Aug 6, 2023
Drug: SPL84 · For: Cystic Fibrosis
Sites: Jerusalem, Israel
Newest research
PubMed records naming it or its code names, newest first.
- A phase 2a study with SPL84: A novel RNA-targeted approach to restore CFTR function in people with CF carrying the 3849+10ߕkb CT mutation.
Cofta S, Springer D, Malakauskas K, et al. · Eur Respir J 2026
- Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis.
Stanleigh N, Irony-Tur Sinai M, Oren Y, et al. · J Cyst Fibros 2026
- SPL84 and trikafta® exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb CT/F508del CFTR variants.
Cheng Y, Oren YS, Harrington J, et al. · J Cyst Fibros 2026
- A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T.
Caraco Y, Wanounou M, Blotnick S, et al. · J Cyst Fibros 2025
- Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849ߙ+ߙ10ߙkb C- > T Cystic Fibrosis Patients.
Ozeri-Galai E, Friedman L, Barchad-Avitzur O, et al. · Nucleic Acid Ther 2023
- The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study.
Friedman L, Avitzur OB, Galai EO, et al. · Expert Opin Drug Metab Toxicol 2023
Also in development for Cystic Fibrosis
- VX-121D-IVA, CTP-656Phase 33 trials
Vertex Pharmaceuticals · Cystic Fibrosis
- ARCT-032Phase 21 trial
Arcturus Therapeutics, Inc. · Cystic Fibrosis, CFTR Gene Mutation
- CMTX-101Phase 21 trial
Clarametyx Biosciences, Inc. · Persistent Infection, Cystic Fibrosis
- ETD001Phase 21 trial
Enterprise Therapeutics Ltd · Cystic Fibrosis
- RCT2100Phase 21 trial
ReCode Therapeutics · Cystic Fibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.